Full Press Release Details
Australian Cancer Treatment Company
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
PRIMA BIOMED ISSUES THE FOLLOWING
NOTICE UNDER SECTION
708A(5)(e) OF THE CORPORATIONS ACT AND APPENDIX 3B
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the
Company ) has announced this notice is given by Prima BioMed Ltd ABN 90 009 237 889 (Company) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).
The Company has today issued 16,412,500 fully paid ordinary shares (Shares) to certain sophisticated and professional
investors (as those terms are defined in section 708 of the Corporations Act) from the shortfall from the Company s recently completed Share purchase plan.
For the purposes of section 708A(6) of the Corporations Act, the Company advises that:
(a) the Shares were issued to investors without disclosure under Part 6D.2 of the Corporations Act;
(b) this notice is being given under section 708A(5)(e) of the Corporations Act;
(c) as at the date of this notice, the Company has complied with:
(i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
(ii) section 674 of the Corporations Act,
at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.
An Appendix 3B in relation to the issue of Shares noted above is attached.
Prima BioMed is a globally
active leader in the development of personalised bio-therapeutic products for cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to
shareholders. Prima BioMed s lead product is CVacTM, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission and soon starting in trials for pancreatic, colorectal, and triple-negative
For further information please contact:
Ms. Jessica Brown, Prima BioMed Ltd.
710-9061; jessica.brown@primabiomed.com.au
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; james@mandatecorporate.com.au
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
905505-52; amuehlhaus@edicto.de
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
New issue announcement,
application for quotation
of additional securities
Information or documents not available now must be given to ASX as soon as available. Information and documents given to
ASX become ASX s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended
01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13
Prima BioMed Ltd (Company)
We (the entity) give ASX the following information.
You must complete the relevant sections (attach sheets if there is not enough space).
1 +Class of +securities issued or to be issued
Fully Paid Ordinary Shares (PRR)
2 Number of +securities issued or to be issued (if known) or maximum number which may be issued
a) 16,412,500 Shares issued to certain sophisticated and professional investors in accordance with the shareholder approval obtained at the EGM on 16 May 2013 to issue SPP shares shortfall
shares (Shortfall Placement)
b) 3 shares issued following the exercise of an equivalent number of quoted
options (Options Exercise).
3 Principal terms of the +securities (e.g. if options, exercise price and expiry
date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
Pari passu with existing Ordinary Fully Paid Shares (PRR)
4 Do the +securities rank equally in all respects from the +issue date with an existing
+class of quoted +securities?
If the additional +securities do not rank equally, please state:
the date from which they do
the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest
5 Issue price or consideration
a) $0.08 per Share (with respect to the Shares issued under the Shortfall Placement)
b) $0.20 per Share (with respect to the Shares issued following the Options Exercise).
6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
a) Shortfall Placement The funds raised under the Shortfall Placement will be applied towards:
- co-funding up to three phase 2 trials of CVac in additional cancer indications and continuing the ongoing clinical
program; - continuing CVac manufacturing optimisation programs to move toward a commercially successful and global product manufacturing platform; and - providing general working capital for the Company and adding security to the balance sheet.
b) Exercise of Options General working capital.
6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?
If Yes, complete sections 6b 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i
6b The date the security holder resolution under rule 7.1A was passed
6c Number of +securities issued without security holder approval under rule 7.1
6d Number of +securities issued with
security holder approval under rule 7.1A
6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval
(specify date of meeting)
16,412,500 shares issued with member approval under listing rule 7.3 obtained at the
Company s general meeting held on 16 May 2013.
6f Number of +securities issued under an exception in rule
6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the
6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
6i Calculate the entity s remaining issue capacity under rule 7.1 and rule 7.1A complete Annexure 1 and release to ASX Market Announcements
Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the
issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.
reference: item 33 of Appendix 3B.
8 Number and +class of all +securities quoted on ASX (including the +securities in
section 2 if applicable)
Ordinary fully paid shares (ASX: PRR)
Options exercisable at $0.20 on or before 19 June 2017 (PRRO)
9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)
Exercise Price Expiration Date
1,884,253 $0.2685 9 November 2014 PRRAS
1,884,253 $0.2360 8 December 2014 PRRAU
1,061,411 $0.2271 12 January 2015 PRRAY
$0.2345 12 February 2015 PRRAW
1,075,269 $0.2277 18 March 2015 PRRAZ
500,000 $0.2500 6 May 2015 PRRAC
1,055,011 $0.2351 19 May 2015 PRRAD
$0.2000 6 December 2013 PRRAL
2,000,000 $0.1000 6 December 2014 PRRAL
500,000 $0.1000 26 August 2014 PRRAL
740,741 $0.3390 1 February 2016 PRRAL
$0.2790 3 November 2014 PRRAL
100,000 $0.2329 3 January 2015 PRRAL